Novel therapies—dabigatran (direct inhibitor of prothrombin) [8], rivaroxaban, and apixaban (direct Xa inhibitor) [18, 19]—proved to be at least as effective as warfarin to prevent stroke in patients with AF. This evidence concerns the gene F2 and atrial fibrillation.